Searchable abstracts of presentations at key conferences in endocrinology

Endocrine Abstracts

Published by BioScientifica

Page 1 of about 2 results

ea0042oc13 | (1) | Androgens2016

The role of nuclear steroid receptors in castration-resistant prostate cancer (CRPC)

Nowakowska Karolina , Riisnaes Ruth , Rodrigues Daniel Nava , Wetterskog Daniel , Jayaram Anuradha , Zaferiou Zafeiris , Mateo Joaquin , de Bono Johann S , Attard Gerhardt

With the wide-spread use of abiraterone/enzalutamide for CRPC, there is an urgent need to understand and reverse resistance to these treatments. Studies have implicated glucocorticoid receptor (GR) as activating androgen receptor (AR) signalling and driving resistance. Here we studied progesterone receptor (PR), which is phylogenetically most closely related to the AR. We first used digital droplet PCR in prostate cancer (PCa) cell lines and observed >10 times higher level...
0 shares

ea0099oc13.1 | Oral Communications 13: Late Breaking | ECE2024

BCL2 expression is enriched in androgen receptor-negative advanced prostate cancer:

Jimenez-Vacas Juan M , Westaby Daniel , Figueiredo Ines , Rekowski Jan , Pettinger Claire , Gurel Bora , Bogdan Denisa , Buroni Lorenzo , Neeb Antje , Padilha Ana , Taylor Joe , Zeng Wanting , Das Souvik , Hobern Emily , Riisnaes Ruth , Crespo Mateus , Miranda Susana , Ferreira Ana , Hanratty Brian , Nava Rodrigues Daniel , Bertan Claudia , Seed George , Fenor de La Maza Maria de Los Dolores , Guo Christina , Carmichael Juliet , Grochot Rafael , Chandran Khobe , Stavridi Anastasia , Varkaris Andreas , Stylianou Nataly , Hollier Brett , Tunariu Nina , Balk Steven , Carreira Suzanne , Yuan Wei , Nelson Peter , Corey Eva , Haffner Michael , de Bono Johann , Sharp Adam

Background: Treatment resistance in prostate cancer can be the result of multiple different tumour cell adaptations generating castration-resistant prostate cancer (CRPC). Despite advancements in treatment, CRPC remains a highly lethal disease. Some CRPCs become AR independent with loss of AR expression and lineage plasticity, urgently requiring novel therapeutic strategies. BCL2 can be upregulated in some CRPCs and may be a therapeutic target for this disease subset.<p cl...
0 shares

Published by BioScientifica

Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 | Privacy policy | Cookie settings

BiosciAbstracts

Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.

Find out more